About the Author
Dr. Khodamoradi is an internal medicine resident in Shiraz University of Medical Sciences, Shiraz, Iran. Her primary research interests focus on internal medicine, gastroenterology, rheumatology, and cardiology.

References
1. Khodamoradi Z, Moghadami M, Lotfi M. Co-infection of coronavirus disease 2019 and influenza A: a report from Iran. Arch Iran Med. 2020;23:239–43. https://doi.org/10.34172/aim.2020.04
2. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18:1094–9. https://doi.org/10.1111/jth.14817
3. Ng KH, Wu AK, Cheng VC, Tang BS, Chan CY, Yung CY, et al. Pulmonary artery thrombosis in a patient with severe acute respiratory syndrome. Postgrad Med J. 2005;81:1c3. https://doi.org/10.1136/pgmj.2004.030049
4. Danzi GB, Loffi M, Galeazzi G, Gherbesi E. Acute pulmonary embolism and COVID-19 pneumonia: a random association? Eur Heart J. 2020 Mar 30:ehaa254; Epub ahead of print. https://doi.org/10.1093/eurheartj/ehaa254
5. Xie Y, Wang X, Yang P, Zhang S. COVID-19 complicated by acute pulmonary embolism. Radiology. Cardiothoracic Imaging. 2020;2:e200067. https://doi.org/10.1148/ryct.2020200067
6. Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med. 2020;382:e1–17. https://doi.org/10.1056/NEJMc2007575
7. Clinton CM, Kuller JA, James AH. Prevention of postpartum venous thromboembolism. Obstet Gynecol Surv. 2019;74:601–6. https://doi.org/10.1097/OGX.0000000000000714
8. American College of Obstetricians and Gynecologists. ACOG practice bulletin no. 196: thromboembolism in pregnancy. Obstet Gynecol. 2018;132:e1–17. https://doi.org/10.1097/AOG.0000000000002706
9. Levi M, van der Poll T. Coagulation and sepsis. Thromb Res. 2017;149:38–44. https://doi.org/10.1016/j.thromres.2016.11.007

Address for correspondence: Shahrokh Sadeghi Boogar, Department of Internal Medicine, Shiraz University of Medical Sciences, Shiraz, Iran; email: sadeghi_sh@sums.ac.ir

Panton-Valentine Leukocidin–Secreting Staphylococcus aureus Pneumonia Complicating COVID-19

Claire Duployez, Rémi Le Guern, Claire Tinez, Anne-Laure Lejeune, Laurent Robriquet, Sophie Six, Caroline Loïez, Frédéric Wallet

Author affiliations: Centre Hospitalier Universitaire Lille, Lille, France (C. Duployez, R. Le Guern, C. Tinez, A.-L. Lejeune, L. Robriquet, S. Six, C. Loïez, F. Wallet); University of Lille (C. Duployez, R. Le Guern, A.-L. Lejeune)

DOI: https://doi.org/10.3201/eid2608.201413

Necrotizing pneumonia induced by Panton-Valentine leukocidin–secreting Staphylococcus aureus is a rare but life-threatening infection that has been described in patients after they had influenza. We report a fatal case of this superinfection in a young adult who had coronavirus disease.

Panton-Valentine leukocidin (PVL) is a cytotoxin produced by some strains of Staphylococcus aureus. These strains are responsible for primary skin infections and necrotizing pneumonia. This rare entity is mainly described in young immunocompetent patients with an influenza-like prodrome and has a high case-fatality rate (1,2). We report a case of necrotizing pneumonia induced by PVL-secreting methicillin-susceptible S. aureus in a patient infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and who had coronavirus disease (COVID-19).

In March 2020, during the SARS-CoV-2 outbreak in France, a man in his 30’s who had no underlying conditions came to an emergency department because of fever, cough, and blood-streaked sputum that developed for 3 days. A diagnosis of pleuropneumonia was made, and antimicrobial therapy was initiated with cefotaxime plus metronidazole. Test results for Streptococcus pneumoniae and Legionella pneumophila serotype 1 urinary antigens were negative. A reverse transcription PCR specific for respiratory viruses also showed negative results.

The next day, further respiratory deterioration required transfer of the patient to an intensive care unit (ICU) for intubation, mechanical ventilation, and inotropic support. Spiramycin was added to the previous drug regimen. Chest computed tomography showed a parenchymal consolidation of the left
upper lung without ground-glass opacities commonly described for COVID-19 (3).

Four days after intubation, the condition of the patient had not improved. We performed a reverse transcription PCR specific for SARS-CoV-2 on an endotracheal aspirate by using the method developed by the National Reference Centre for Respiratory Viruses (Institut Pasteur, Paris, France). The PCR result was positive for SARS-CoV-2 (4). Chest computed tomography showed worsening of bilateral parenchymal damage with complete consolidation of the left lung, cavitary lesions suggestive of multiple abscesses, and appearance of areas of ground-glass opacities in the right lung (Figure). The chest radiograph also showed a left pleural effusion.

Bacteriological analysis of pleural drainage showed gram-positive cocci; the culture yielded monomicrobial S. aureus, which was identified by using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (Bruker Daltonics, https://www.bruker.com). The bacterial strain was resistant only to penicillin G (VITEK 2 System; bioMérieux, https://www.biomerieux.com). Because of this necrotizing pneumonia associated with acute respiratory distress syndrome, a PVL-producing strain was suspected. We confirmed PVL production by using a specific PCR as described by Deurenberg et al. (5).

We changed antimicrobial drug therapy to oxacillin plus clindamycin (for antitoxin effect) against methicillin-susceptible S. aureus and lopinavir/ritonavir (quickly stopped because of suspected toxicity) plus azithromycin against SARS-CoV-2. Three days later, given a lack of clinical improvement, antimicrobial therapy was changed to piperacillin/tazobactam plus linezolid (for antitoxin effect). Bronchoscopy showed that the left bronchial tree was obstructed by purulent secretions. Because of deterioration of respiratory, renal, and liver functions, venovenous extracorporeal membrane oxygenation and anticoagulation were initiated 10 days after ICU admission. Two days later, we performed upper lobectomy, and antimicrobial drug therapy was incremented with meropenem, gentamicin, and linezolid. However, the patient died 17 days after his admission to the hospital.

PVL-secreting S. aureus necrotizing pneumonia is frequently preceded by an influenza-like infection (6), which might be a possible causative factor. Influenza virus is known to impede phagocytic killing and damage the bronchial epithelium, thus reducing secretin clearance and facilitating bacteria adhesion (2). It also induces an influx of immune cells to lung tissues, including neutrophils; the rapid killing of these cells by PVL and release of inflammatory mediators might promote disease development by damaging the epithelium (7,8). The association of PVL-secreting S. aureus and influenza virus has been reported (6,9). We report a PVL-secreting S. aureus superinfection in a patient who had COVID-19. Our findings indicate that the new SARS-CoV-2 is, in the same way, a facilitating factor for PVL-producing S. aureus necrotizing pneumonia.

In 2003, during the SARS-CoV outbreak, an increase in S. aureus superinfection (mostly methicillin-resistant S. aureus ventilator-acquired pneumonia) was described. Given common points between SARS-CoV-2 and previous coronaviruses, Lupia et al. discussed this issue for COVID-19 and suggested consideration of methicillin-resistant S. aureus coverage to reduce the risk of superinfection (10).

In PVL-producing S. aureus superinfection, prescribing antimicrobial drugs that have an antitoxin effect, such as clindamycin or linezolid, remains essential (2). Thus, in previously healthy young adults admitted to an ICU for COVID-19 and S. aureus superinfection, a PVL-producing strain should be assumed and treatment provided accordingly.

About the Author
Dr. Duployez is a microbiologist at Centre Hospitalier Universitaire Lille, Lille, France. Her primary research interest is medical diagnosis of bacterial diseases.
We report 3 patients with coronavirus disease who had a decline in respiratory status during their hospital course that responded well to intravenous steroids and interleukin-6 receptor antagonist therapy. These patients later showed development of persistent hypoxia with increased levels of d-dimer levels and were given a diagnosis of pulmonary embolisms.

**Coronavirus disease (COVID-19)**, caused by severe acute respiratory syndrome coronavirus 2, has been extensively reported since the outbreak in Wuhan, China, and can progress to involve major respiratory complications (1). Patients commonly have fever, cough, abdominal pain, and diarrhea.

During the second week of illness, decompensation occurs in some patients, possibly driven by the cytokine storm associated with increased levels of interleukin-6. We report 3 case-patients with COVID-19 who were improving after successful treatment during the critical period but showed development of pulmonary embolisms.

Three patients admitted to Northwell Plainview Hospital (Plainview, NY, USA) showed positive results for COVID-19 and had acute hypoxic respiratory failure secondary to COVID-19. All 3 patients received azithromycin and hydroxychloroquine, but their conditions continued to progress to more severe respiratory failure. During what was assumed to be the cytokine storm phase, on the basis of laboratory parameters and an increasing requirement for oxygen, the patients received intravenous steroids (solumedrol, 1–2 mg/kg/d for 5–8 d) and the interleukin-6 receptor antagonist tocilizumab (400 mg

---

**References**

1. Gillet Y, Issartel B, Vanhems P, Fournet JC, Lina G, Bes M, et al. Association between *Staphylococcus aureus* strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet. 2002;359:753–9. https://doi.org/10.1016/S0140-6736(02)07877-7

2. Kreienbuehl L, Charbonney E, Eggimann P. Community-acquired necrotizing pneumonia due to methicillin-sensitive *Staphylococcus aureus* secreting Panton-Valentine leukocidin: a review of case reports. Ann Intensive Care. 2011;1:52. https://doi.org/10.1186/2110-5820-1-52

3. Kooraki S, Hosseiny M, Myers L, Gholamrezanezhad A. Coronavirus (COVID-19) outbreak: what the Department of Radiology should know. J Am Coll Radiol. 2020;17:447–51.

4. Bernard Stoecklin S, Rolland P, Silue Y, Mailles A, Campese C, Simondon A, et al.; Investigation Team. First cases of coronavirus disease 2019 (COVID-19) in France: surveillance, investigations and control measures, January 2020. Euro Surveill. 2020;25. https://doi.org/10.2807/1560-7917.ES.2020.25.6.2000094

5. Deurenberg RH, Vink C, Diessink C, Bes M, London N, Etienne J, et al. Rapid detection of Panton-Valentine leukocidin from clinical isolates of *Staphylococcus aureus* strains by real-time PCR. FEMS Microbiol Lett. 2004;240:225–8. https://doi.org/10.1016/j.femsle.2004.09.031

6. Jacquot A, Luyt CE, Kimmoun A, Levy B, Baux E; Fluvalentine Study group. Epidemiology of post-influenza bacterial pneumonia due to Panton-Valentine leukocidin positive *Staphylococcus aureus* in intensive care units: a retrospective nationwide study. Intensive Care Med. 2019;45:1312–4. https://doi.org/10.1007/s00134-019-05665-3

7. Niemann S, Ehrhardt C, Medina E, Warning K, Tuchscherr L, Heitmann V, et al. Combined action of influenza virus and *Staphylococcus aureus* Panton-Valentine leukocidin provokes severe lung epithelium damage. J Infect Dis. 2012;206:1138–48. https://doi.org/10.1093/infdis/jis468

8. Löffler B, Niemann S, Ehrhardt C, Horn D, Lanckohr C, Lina G, et al. Pathogenesis of *Staphylococcus aureus* necrotising pneumonia: the role of PVL and an influenza coinfection. Expert Rev Anti Infect Ther. 2013;11:1041–51. https://doi.org/10.1586/14787210.2013.827891

9. Riedweg-Moreno K, Walfert F, Blażejewski C, Godard A, Spennemann D, Weller M; Fluvalentine Study group. Successful management of Panton-Valentine leukocidin-provoked severe lung epithelium damage. J Glob Antimicrob Resist. 2020;21:22–7. https://doi.org/10.1016/j.jgar.2020.02.021

Address for correspondence: Claire Duployez, Laboratoire de Bactériologie, Institut de Microbiologie, Centre de Biologie Pathologique, F-59037 Lille CEDEX, France; email: claire.duployez@chru-lille.fr